1. Home
  2. RVSN vs ICU Comparison

RVSN vs ICU Comparison

Compare RVSN & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

HOLD

Current Price

$4.45

Market Cap

10.9M

Sector

N/A

ML Signal

HOLD

Logo SeaStar Medical Holding Corporation

ICU

SeaStar Medical Holding Corporation

HOLD

Current Price

$3.55

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSN
ICU
Founded
2016
2018
Country
Israel
United States
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
9.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RVSN
ICU
Price
$4.45
$3.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
18.1K
80.3K
Earning Date
03-31-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$860.32
$53.00
Revenue Next Year
N/A
$50.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.22
52 Week High
$9.39
$5.10

Technical Indicators

Market Signals
Indicator
RVSN
ICU
Relative Strength Index (RSI) 29.87 51.60
Support Level $4.20 $2.26
Resistance Level $5.21 $4.96
Average True Range (ATR) 0.33 0.29
MACD 0.07 0.06
Stochastic Oscillator 14.28 79.43

Price Performance

Historical Comparison
RVSN
ICU

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: